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http://dx.doi.org/10.1016/j.ccr.2014.06.006SUMMARYMdm2 E3 ubiquitin ligase-mediated p53 degradation is generally accepted as the major mechanism for p53
regulation; nevertheless, the in vivo significance of this function has not been unequivocally established.
Here, we have generated an Mdm2Y487A knockin mouse; Mdm2Y487A mutation inactivates Mdm2 E3 ligase
function without affecting its ability to bind its homolog MdmX. Unexpectedly, Mdm2Y487A/Y487A mice were
viable and developed normally into adulthood. While disruption of Mdm2 E3 ligase function resulted in p53
accumulation, p53 transcriptional activity remained low; however, exposure to sublethal stress resulted in
hyperactive p53 and p53-dependent mortality in Mdm2Y487A/Y487A mice. These findings reveal a potentially
dispensable nature for Mdm2 E3 ligase function in p53 regulation, providing insight that may affect how
this pathway is targeted therapeutically.INTRODUCTION regulating p53 protein levels, Mdm2 also regulates p53 activityClassically, p53 has been characterized as a tumor suppressor,
functioning as a transcription factor for a number of genes
important in the regulation of cell cycle arrest, apoptosis, and
senescence (Levine, 1997). In more recent years, a multitude
of research has emerged, demonstrating p53 to also be critical
in meiosis, reproduction, and metabolism, further broadening
the role of p53 (Levine et al., 2011; Lu et al., 2010; Vousden
and Ryan, 2009).
The oncoprotein Mdm2 is generally accepted to function as
the primary negative regulator of p53 (Kruse and Gu, 2009;
Wade et al., 2010). The RING finger domain of Mdm2 confers
its E3 ubiquitin ligase activity, and through this function Mdm2
controls p53 stability, targeting it for export from the nucleus
and subsequent degradation by the proteasome (Haupt et al.,
1997; Honda et al., 1997; Kubbutat et al., 1997). In addition toSignificance
Classically characterized as an overarching tumor suppresso
human cancers. Inhibition of Mdm2 E3 ubiquitin ligase-mediate
anism for p53 activation and serves as the underpinning of
observed in ourMdm2Y487A knockinmouse, inactivation ofMdm
action does not efficiently activate p53; however, disruption
induced DNA damage and lethality. This study provides insi
the current problems surrounding the development of effectivby binding via its N terminus directly to the p53 transactivation
domain (Momand et al., 1992; Oliner et al., 1993). In vivo, deletion
ofMdm2 results in high levels of p53 protein and transcriptional
activity, and early embryonic lethality in Mdm2/ mice; this
phenotype is rescued by concomitant deletion of Trp53, further
demonstrating the essential role of Mdm2 in p53 regulation
(Jones et al., 1995; Montes de Oca Luna et al., 1995).
MdmX, anMdm2 homolog, is similarly capable of binding at its
N terminus to the p53 transactivation domain to control p53 ac-
tivity; however, MdmX does not harbor intrinsic E3 ubiquitin
ligase activity (Jackson and Berberich, 2000; Poyurovsky et al.,
2007; Shvarts et al., 1996). Similar to Mdm2/ mice, p53-
dependent early embryonic lethality is also observed in
Mdmx/ mice (Parant et al., 2001). While the early embryonic
lethality observed in both Mdm2 and Mdmx knockout mouse
models suggests that individually Mdm2 and MdmX play uniquer, p53 is frequently mutated, deleted, and misregulated in
d degradation of p53 is considered to be an essential mech-
many cancer treatments aimed at reactivation of p53. As
2 E3 ligase function without obliteratingMdm2:MdmX inter-
of Mdm2 E3 ligase function sensitizes mice to irradiation
ght into the Mdm2-p53 regulatory loop and sheds light on
e cancer therapeutics targeting the p53 pathway.
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In Vivo Function of Mdm2 E3 Ubiquitin Ligaseand critical roles in the regulation of p53 activity, the embryonic
lethality observed in two recently developed Mdmx knockin
mouse models that disrupt Mdm2:MdmX heterodimerization
suggests that the ability of these two proteins to interact at their
respective C-terminal RING finger domains and function collab-
oratively is essential for p53 regulation (Huang et al., 2011; Pant
et al., 2011).
Mdm2:MdmX heterodimerization is also disrupted by muta-
tion of the Mdm2 RING finger domain, as observed in the
Mdm2C462A knockin mouse model (Clegg et al., 2012; Itahana
et al., 2007). This mutation substitutes cysteine 462 of murine
Mdm2 to alanine, thus disrupting Mdm2:MdmX interaction and
ablating Mdm2 E3 ligase activity, but maintaining Mdm2:p53
interaction. Homozygous Mdm2C462A mutation results in early
embryonic lethality due to excessive p53 activation, suggesting
that Mdm2:p53 binding alone is insufficient for controlling
p53 activity and calling into question the extent to which
Mdm2:p53 interaction can regulate p53 activity in vivo (Itahana
et al., 2007). Because both Mdm2 E3 ligase activity and
Mdm2:MdmX heterodimerization are disrupted by the
Mdm2C462A mutation, the independent effect of loss of each of
these RING finger domain functions cannot be deduced from
thismodel. Therefore, the in vivo role of Mdm2E3 ubiquitin ligase
activity, believed to be a critical Mdm2 function in p53 regulation,
is yet to be unequivocally addressed. We carried out the current
study to address this question.
RESULTS
Mdm2Y487A/Y487A Mice Are Viable and Phenotypically
Normal
In vitro, the extreme C-terminal 5 amino acids of Mdm2 are
necessary for E3 ubiquitin ligase activity; mutations within this
region disrupt Mdm2 E3 ligase activity, without affecting its abil-
ity to homo-oligomerize with Mdm2 or hetero-oligomerize with
MdmX (Poyurovsky et al., 2007; Uldrijan et al., 2007). Specif-
ically, retention of an aromatic amino acid at the residue 489 of
human Mdm2 is essential for Mdm2 E3 ligase activity, and Tyr-
to-Ala mutation (Y489A) ablates Mdm2 E3 ligase activity without
affecting its interaction with MdmX (Uldrijan et al., 2007). In vitro
characterization of themouseMdm2Y487A recapitulated the pub-
lished study of the corresponding human Mdm2Y489A; expres-
sion of both the human and mouse mutant Mdm2 in U2OS cells
correlated with accumulation of ectopically expressed and
endogenous p53 (Figures S1A–S1D available online). Further-
more, co-overexpression of MdmX with Mdm2Y487A resulted in
p53 levels similar to that observed in the presence of wild-type
(WT) Mdm2, in agreement with observations made in the humanFigure 1. Generation of Mdm2Y487A Knockin Mice
(A) Schematic representation of the Mdm2 targeting vector. Solid boxes repre
represent the last sixMdm2 exons. Triangles indicate the presence and orientatio
mutation at the 487 amino acid residue.
(B) PCR amplification of genomic DNA isolated from toe snips of mouse pups.
(C) Sequencing analysis of genomic DNA isolated from offspring ofMdm2Y487A/+
with arrows in (A), and sequenced.
(D) Observed and expected birth ratios from Mdm2Y487A/+ intercrosses; total of 3
(E) Mdm2+/+, Mdm2Y487A/+, and Mdm2Y487A/Y487A mice were weighed and obser
(F) Mdm2+/+, Mdm2Y487A/+, and Mdm2Y487A/Y487A male and female mice were ob
See also Figure S1.Mdm2Y489A, and indicative of a potential role for MdmX in
improving, and at times rescuing, Mdm2 E3 ligase activity (Oka-
moto et al., 2009; Poyurovsky et al., 2007; Uldrijan et al., 2007).
Titration of MdmX demonstrated that coexpression of MdmX
with mutant Mdm2 at a 1:1 ratio reduced p53 stabilization, but
when MdmX was coexpressed with Mdm2 at a 1:5 or 1:10 ratio,
similar to ratios previously observed in human cells (Wang et al.,
2009; Wang et al., 2007), a greatly diminished effect on p53 sta-
bility was noted, pointing to the importance of the relative levels
of Mdm2 and MdmX in their function (Figures S1E and S1F).
To assess if the Mdm2Y487A mutant maintains this phenotype
in vivo, site directed mutagenesis was used to introduce a Tyr
487-to-Ala substitution in mouse genomic Mdm2 (Figure 1A).
Correct substitution of TAC to GCA in exon 12 of Mdm2 was
confirmed via DNA sequencing. The targeting vector containing
the Mdm2 Y487A substitution was injected into 129/Sv embry-
onic stem (ES) cells, and the ES cells were then microinjected
into C57BL/6 blastocysts to produce chimeras. Following mat-
ing of chimericmalemicewith C57BL/6 females, PCR (Figure 1B)
and sequencing (Figure 1C) of mouse genomic DNA were used
to confirm germline transmission of the Mdm2Y487A mutation.
The neomycin cassette was removed from the neo-Mdm2Y487A/+
mice bymating against an EIIa-Cre transgenic mouse, which tar-
gets expression of Cre recombinase early in mouse embryogen-
esis, providing fairly ubiquitous excision of the marker from the
targeted allele in the mouse. Further intercrossing of Cre-treated
mice was performed to outbreed the Cre-transgene, followed by
five generations of backcrossing to C57BL/6 to generate mutant
mice with a 97% C57BL/6 genetic background.
Mice heterozygous for Mdm2Y487A were viable and appeared
phenotypically normal and fertile. Surprisingly, upon intercross-
ing Mdm2Y487A/+ mice, Mdm2Y487A/Y487A mice were observed
at normal Mendelian ratios at birth, indicating that no embryonic
lethality is associated with homozygosity of this mutation (Fig-
ure 1D). To determine if the mutation had effects later in develop-
ment, a cohort of male and female mice was assembled and
monitored weekly for weight, activity, and overt signs of disease.
Both male and female homozygous mutant mice appeared to be
somewhat smaller than their heterozygous andWT counterparts
(Figure 1E). Mdm2Y487A/Y487A mice did not demonstrate any
notable differences in disease occurrence, spontaneous tumor
formation, or mortality compared to WT mice (Figure 1F).
Endogenous Mdm2Y487A Does Not Degrade p53, but
Maintains Normal Binding Dynamics
The viability and apparent normality of Mdm2Y487A/Y487A mice
was surprising; thus, we examined endogenous Mdm2Y487A to
determine its E3 ligase function and its ability to interact withsent regions of vector homology to the target locus; thick numbered boxes
n of loxP sites. Site directed mutagenesis was used to introduce the Tyr-to-Ala
heterozygous intercrosses. DNA was PCR amplified, primer location indicated
02 offspring observed.
ved weekly. Data represent means ± SEM.
served weekly for activity and viability. Kaplan-Meier survival curve is shown.
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In Vivo Function of Mdm2 E3 Ubiquitin LigaseMdmX. In some tissue types, such as the spleen and testes,
and in mouse embryonic fibroblasts (MEFs), increased levels of
p53 were observed in the Mdm2Y487A/Y487A mutant compared
to the WT, suggestive of disrupted Mdm2 E3 ligase activity for
p53 degradation; this increase was more dramatic in MEFs
compared to tissues (Figures 2A and 2B). While somewhat
higher p21 levels were observed in some Mdm2Y487A/Y487A
tissues, potentially indicative of higher p53 activity, in
Mdm2Y487A/Y487A MEFs, elevated levels of p53 did not lead
to increased levels of the p53 targets p21 and Apaf1, sug-
gesting that p53 transcriptional activity is not increased in
Mdm2Y487A/Y487A MEFs.
Tomore directly analyze the E3 ligase activity ofMdm2Y487A for
p53, a half-life assay using the protein synthesis inhibitor cyclo-
heximide was performed in Mdm2+/+ and Mdm2Y487A/Y487A
MEFs. In the presence of WT Mdm2, p53 has a half-life of
approximately 30 min; however, in the presence of only
Mdm2Y487A, no degradation of p53 was observed (Figure 2C).
Further, following treatment with the proteasome inhibitor
MG-132, p53 was significantly accumulated in WT MEFs,
whereas in Mdm2Y487A/Y487A MEFs, no further accumulation of
p53 was observed (Figure 2E). The increased levels of p53 under
unstressed conditions and the lack of p53 accumulation by
MG-132 treatment in Mdm2Y487A/Y487A MEFs suggest that loss
of Mdm2 E3 ligase activity significantly disrupts proteasome-
mediated degradation of p53, and supports the role of Mdm2
as the primary E3 ubiquitin ligase for p53 degradation in vivo.
In agreement with previous in vitro studies showing that
Mdm2Y489A does not degrade p53 (Poyurovsky et al., 2007; Ul-
drijan et al., 2007), these data demonstrate that endogenous
Mdm2Y487A has similarly lost this function.
WhileMdm2Y487A/Y487Amice are viable in the presence of p53,
in order to directly compare this mutant to the embryonic lethal
Mdm2C462A/C462A mutant (Itahana et al., 2007), an inducible
p53 background, p53ERTAM (p53ER hereafter), was utilized. In
the p53ER background, endogenous p53 is substituted with a
p53 fusion protein, providing the ability for p53 to be turned
‘‘on’’ and ‘‘off’’ in the presence and absence of 4-hydroxytamox-
ifen (4-OHT), respectively (Christophorou et al., 2005). Similar to
MEFs harboring the Mdm2C462A RING domain mutant, half-life
assay of Mdm2Y487A/Y487A;p53ER/- MEFs demonstrated no
degradation of p53ER (Figure 2D). Furthermore, as demonstrated
by immunoprecipitation of Mdm2 in MEFs, Mdm2Y487A mutantFigure 2. Mdm2Y487A Is Unable to Degrade p53, but Maintains Normal
(A) Lysates from the spleen, thymus, testes, and brain of 8-week old Mdm2+/+ (W
p53 and p21 levels. Actin was used as a loading control.
(B) Early passage Mdm2+/+ (WT) and Mdm2Y487A/Y487A (487/487) MEF cell lysate
used as a loading control.
(C) Early passage Mdm2+/+ and Mdm2Y487A/Y487A MEFs were treated with 100 m
indicated. The levels of p53 and actin were analyzed by western blotting. The amo
plotted.
(D) Levels of p53ER were measured and analyzed as in (C).
(E)Mdm2+/+ (WT) andMdm2Y487A/Y487A (487/487) MEFs were treated with 25 mM
analyzed by western blotting. Actin was used as a loading control.
(F)Mdm2+/+ andMdm2Y487A/Y487AMEFs were immunoprecipitated and immunob
utilized for IP. Mdm2C462A/C462A;p53/ MEFs were utilized as a negative contro
(G)Mdm2+/+;p53ER/- andMdm2Y487A/Y487A;p53ER/-MEFs were immunoprecipitate
MEFs were utilized as a negative control for Mdm2:MdmX binding.
See also Figure S2.protein maintains the ability to bind to MdmX, p53, and p53ER
(Figures 2F and 2G).
Mdm2 has previously been identified as the E3 ligase respon-
sible for MdmX degradation (Kawai et al., 2003; Linke et al.,
2008; Pan and Chen, 2003), and as expected, in the presence
of Mdm2Y487A, stabilization of MdmX is observed (Figures 2F
and 2G). A cycloheximide mediated half-life assay indicated
that the degradation of MdmX is indeed attenuated in the pres-
ence of Mdm2Y487A (Figures S2A and S2B). Moreover, while total
protein levels of p53, Mdm2, and MdmX are increased in
Mdm2Y487A/Y487A MEFs, the subcellular distribution of each of
these proteins remained similar to that observed in WT MEFs
(Figures S2C–S2F). Of note, although Mdm2 and MdmX levels
are increased in the presence of Mdm2Y487A, this increase
does not appear to alter the Mdm2:MdmX ratio sufficiently to
result in efficient degradation of p53 (Figures 2C–2E).
Y487A Mutation Does Not Affect Mdm2 Degradation
The regulation of Mdm2 stability is believed to be mediated pri-
marily through autoubiquitination (Fang et al., 2000; Honda and
Yasuda, 2000; Stommel and Wahl, 2004); however, the advent
of theMdm2C462A knockinmouse provided strong evidence sug-
gesting that Mdm2 does not in fact autoubiquitinate in vivo, but
that instead an unknown E3(s) is responsible for Mdm2 degrada-
tion (Itahana et al., 2007). Nonetheless, the Mdm2C462A model
has a caveat in that it disrupts Mdm2 RING structure, along
with Mdm2 E3 ligase function and Mdm2:MdmX binding, and
the possibility of this structural change adversely affecting
Mdm2 stability cannot be ruled out. With theMdm2Y487A model,
we wanted to further explore the mechanism of Mdm2 degrada-
tion in vivo. Despite disrupting Mdm2-mediated degradation of
p53 andMdmX (Figures 2C, 2D, S2A, and S2B), and higher levels
of Mdm2 in Mdm2Y487A/Y487A MEFs (Figures 2F and 2G), Mdm2
was degraded at a similar rate in Mdm2Y487A/Y487A MEFs as in
WT MEFs (Figure 3A). Similar to previous observations made in
Mdm2C462A/C462A; p53ER/- MEFs (Itahana et al., 2007), a normal
rate of Mdm2 degradation was observed in Mdm2Y487A/Y487A;
p53ER/- MEFs (Figure 3B). To further investigate the mechanism
of Mdm2 degradation, while avoiding the confounding effects of
p53 transcriptional activation ofMdm2, a p53 null genetic back-
ground was utilized. MG-132 treatment resulted in similar stabi-
lization of Mdm2 in Mdm2+/+;p53/, Mdm2Y487A/Y487A;p53/,
and Mdm2C462A/C462A;p53/ MEFs, indicating that Mdm2Binding Dynamics
T) and Mdm2Y487A/Y487A (487/487) mice were analyzed by western blotting for
s were analyzed by western blotting for Apaf1, p53, and p21 levels. Actin was
g/mL cycloheximide and harvested using SDS lysis buffer at the time points
unt of p53 was quantified by densiometry, normalized to the level of actin, and
MG-132 for 5 hr as indicated. Lysates were collected and the level of p53 was
lotted with the indicated antibodies. Loading represents 1% of total cell lysate
l for Mdm2:MdmX binding.
d and immunoblotted with the indicated antibodies as in (F),MdmX/;p53ER/-
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Figure 3. Y487A Mutation Does Not Affect
Mdm2 Degradation
(A) Early passage Mdm2+/+ and Mdm2Y487A/Y487A
MEFs were treated with 100 mg/mL cycloheximide
and harvested using SDS lysis buffer at the time
points indicated. The levels of Mdm2 and actin
were analyzed by western blotting. The amount of
Mdm2 was quantified by densiometry, normalized
to the level of actin, and plotted.
(B) The degradation of Mdm2 in Mdm2+/+;p53ER/-
andMdm2Y487A/Y487A;p53ER/- MEFs was analyzed
as in (A).
(C) Mdm2+/+;p53/, Mdm2Y487A/Y487A;p53/,
and Mdm2C462A/C462A;p53/ MEFs were treated
with 25 mM MG-132 for 8 hr as indicated. Lysates
were collected and the level of Mdm2 was
analyzed by western blotting. Actin was used as a
loading control.
See also Figure S3.
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suggesting the role of an E3 ligase other than Mdm2 itself in
Mdm2 ubiquitination and degradation (Figure 3C).
While both Mdm2Y487A and Mdm2C462A disrupt p53 degrada-
tion and maintain Mdm2 degradation, the location of the Y487
residue, C-terminal of the Mdm2 RING finger domain, should
not disrupt zinc coordination, thus proper folding and the
structure of the RING domain should remain intact (Figure S3)
(Linke et al., 2008). The observation of a second, mechanistically
unique, E3 inactive Mdm2mutant capable of maintaining normal
degradation provides additional evidence against the necessity
of autoubiquitination for in vivo degradation of Mdm2.
Mdm2:MdmX Heterodimerization Is Essential for p53
Suppression
In light of the embryonic lethality observed in MdmxDRING (Pant
et al., 2011), MdmxC462A (Huang et al., 2011), and Mdm2C462A
(Itahana et al., 2007) homozygous mutants, all of which disrupt
Mdm2:MdmX heterodimerization, we sought to use the
Mdm2Y487A model in conjunction with the Mdm2C462A model
for a comparative study of the effect of Mdm2:MdmX heterodi-
merization on p53 activity, independent of the Mdm2 E3 ligase
function. To this end, qRT-PCR was performed to compare the
relative mRNA levels of p53 target genes in MEFs. Upon activa-
tion of p53 with 4-OHT,Mdm2Y487A/Y487A;MdmX+/+;p53ER/- (487/
487) MEFs maintained similarly low levels of mRNA in a number
of p53 target genes, including Mdm2, p21, Apaf1, and Bax, as
compared to Mdm2+/+;MdmX+/+;p53ER/- WT MEFs (Figures 4A240 Cancer Cell 26, 235–247, August 11, 2014 ª2014 Elsevier Inc.and S4A). Disruption of Mdm2:MdmX
heterodimerization via concomitant dele-
tion of MdmX, as in Mdm2Y487A/Y487A;
Mdmx/;p53ER/- (487/487;Mdmx/), or
via Mdm2 RING finger mutation, as in
Mdm2C462A/C462A;Mdmx+/+;p53ER/- (462/
462), was correlated with higher mRNA
levels of p53 and p53 target genes, indic-
ative of higher p53 activity in the absence
of Mdm2:MdmX interaction (Figures 4A
and S4A). The E3 inactive status of theMdm2Y487A mutant in vivo suggests that the function of
Mdm2:MdmX interaction goes beyond E3 ligase activity;
following activation with 4-OHT, p53ER levels are similarly
reduced in both the presence and absence of MdmX (Fig-
ure S4B), indicating that under unstressed conditions the degra-
dation of p53 by Mdm2 does not require MdmX binding.
Together, this suggests that the ability of Mdm2 to heterodimer-
ize with MdmX, but not its E3 ligase activity, is essential for sup-
pression of p53 activity.
To elucidate themechanism by which theMdm2:MdmX heter-
odimer suppresses p53 activity, we assessed p53 acetylation,
an important posttranslational modification for the enhancement
of p53 activity (Gu and Roeder, 1997). While total p53 levels
were comparable between genotypes, a higher level of acety-
lated p53 was observed in Mdm2C462A/C462A;p53ER/- MEFs
lacking Mdm2:MdmX heterodimerization compared to either
Mdm2Y487A/Y487A;p53ER/- or Mdm2+/+;p53ER/- MEFs, both of
which retain intact Mdm2:MdmX heterodimer formation (Fig-
ure 4B). Additionally, loss of heterodimerization correlated with
increased binding between p53 and the histone acetyltrans-
ferase p300 (Figure 4C). This data suggest that Mdm2:MdmX
heterodimerization functions to control p53 activity, at least in
part, through inhibiting p53:p300 interaction and p53 acetylation.
Taking into account the outward normalcy ofMdm2Y487A/Y487A
mice, despite lacking Mdm2 E3 ligase activity, we wanted to
further explore if and when the E3 ligase function of Mdm2 is
necessary. As a transcriptional target of p53,Mdm2 transcription
is stimulated following p53 activation, presumably to degrade
Figure 4. Mdm2:MdmX Heterodimerization
Is Essential for p53 Suppression





MEFs after 4-OHT treatment were measured by
qRT-PCR. All samples were analyzed in triplicate.
Data are means ± SD calculated from three inde-
pendent experiments and normalized to Actin.
**p < 0.01, ***p < 0.001 compared with control
group.
(B) Mdm2+/+;p53ER/-, Mdm2Y487A/Y487A;p53ER/-,
and Mdm2C462A/C462A;p53ER/- MEFs were incu-
batedwith 4-OHT for 4 hr, harvested, and analyzed
by western blotting. Actin was used as a loading
control.
(C) Mdm2+/+;p53ER/-, Mdm2Y487A/Y487A;p53ER/-,
and Mdm2C462A/C462A;p53ER/- MEF lysates were
crosslinked and then immunoprecipitated and im-
munoblotted as indicated. Cells were incubated
with 4-OHT for 4 hr prior to crosslinking.
(D) Expression of p53 target genes, Mdm2, p21,
Bax, Apaf1, and Tigar in Mdm2+/+ (WT) and
Mdm2Y487A/Y487A (487/487) MEFs was measured
by qRT-PCR after 25 J/m2 UV treatment as indi-
cated. Untreated (Untd) MEFs were used as a
control. All samples were analyzed in triplicate
minimally. Data are means ± SD calculated from
three independent experiments and normalized to
GAPDH. **p < 0.01, ***p < 0.001 compared with
control group.
See also Figure S4.
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feedback loop between Mdm2 and p53 (Barak et al., 1993;
Juven et al., 1993). We sought to test whether the absence of
Mdm2 E3 ligase activity, an essential component of the Mdm2-
p53 negative feedback loop, affects the p53-mediated stress
response. Prior to stress, WT and Mdm2Y487A/Y487A MEFs
exhibited relatively low levels of mRNA in a number of well char-
acterized p53 target genes, includingMdm2, the cell cycle regu-
lator p21, and the pro-apoptotic genes Bax, Apaf1, and Tigar, as
determined by qRT-PCR (Figure 4D). However, following UV irra-
diation (IR), Mdm2Y487A/Y487A MEFs demonstrated significantly
higher mRNA levels of the p53 target genes assessed compared
to WT MEFs, indicative of higher levels of p53 activity in the
absence of Mdm2 E3 ligase function (Figure 4D).
To determine if the increased p53 activity observed with UV
activation of the p53 pathway was a more universal response,
qRT-PCR was utilized to analyze the mRNA levels of the
above-mentioned p53 target genes following additional forms
of DNA damage, including 5 Gy g IR, and 1 mM doxorubicin
(Dox), as well as ribosomal stress, as induced by a low dose
(5 nM) of actinomycin D (Act D). Regardless of the stimuli,
Mdm2Y487A/Y487A MEFs were observed to have increased
mRNA levels compared toWTMEFs in all of the p53 target genes
analyzed, although the magnitude of activation varied between
treatments (Figure S4D). Together these data suggest that
although the E3 inactive Mdm2Y487A can suppress p53 in the
absence of stress, it cannot efficiently suppress stress-stimu-
lated hyper-p53 activity.Mdm2 E3 Ligase Function Is Necessary for Recovery
from DNA Damage
Classically, Mdm2 E3 ligase mediated ubiquitination is thought
to be critical in the downregulation of p53 after its stabilization in
response to stress, and thus, we wanted to explore the effect of
the loss of this function on p53 stability and activity following
activation of the p53 stress response pathway. Under untreated
conditions, despite significant differences in total p53 levels,
Mdm2Y487A/Y487A MEFs demonstrated low p53 activity as indi-
cated by levels of p53 phosphorylation (Figures 5A, S5A, and
S5B), p21 protein expression (Figures 2B and 5A), and mRNA
expression of a number of p53 target genes (Figures 4D and
S4D). Following g IR, UV IR, or Dox induced DNA damage,
WT MEFs demonstrated initial stabilization of total p53 and
phosphorylated p53, followed by a return toward low levels;
inMdm2Y487A/Y487AMEFs, sustained high levels were observed
(Figures 5A–5C, S5A, and S4B). The continued increase of total
p53 protein in the mutant MEFs after DNA damage is likely due
to the combined effect of increased p53 transcription (Raman
et al., 2000;Webster and Perkins, 1999) (Figure S5C), increased
p53 translation (Candeias et al., 2008; Gajjar et al., 2012; Takagi
et al., 2005), and the inability of the Mdm2Y487A mutant to
degrade p53. The effect of increased levels of p53 and the cor-
responding increase in p53 activity in Mdm2Y487A/Y487A MEFs
following exposure to DNA damaging reagents is further re-
flected in increased cell cycle arrest (Figure S5D) and
decreased cell survival (Figure S5E). Additionally, we observed
that the growth of WT and Mdm2Y487A/Y487A MEFs was similarCancer Cell 26, 235–247, August 11, 2014 ª2014 Elsevier Inc. 241
Figure 5. Mdm2-Mediated Degradation of
p53 Is Necessary to Regulate p53 Protein
and Activity Levels after Stress
(A) Mdm2+/+ (top) and Mdm2Y487A/Y487A (bottom)
MEFs were treated with 5 Gy X-ray IR, cell lysates
were collected at the indicated time points and
analyzed by western blotting with antibodies to
p53, S-18 phosphorylated p53 (p-p53), and p21.
Actin was used as a loading control.
(B and C) DNA damage induced by 25 J/m2 UV (B)
or 1 mM Dox (C) was utilized to activate the p53
pathway in Mdm2+/+ and Mdm2Y487A/Y487A MEFs,
cell lysates were collected at the indicated time
points and analyzed by western blotting. In (C),
drugs were removed after 4 hr of treatment.
See also Figure S5.
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levels of oxygen, but at 20% O2, the oxidative stress of
standard cell culture conditions was sufficient to reduce cell
growth in otherwise untreated, unstressed Mdm2Y487A/Y487A
MEFs (Figure S5F). Furthermore, 3% O2 cell culturing condi-
tions attenuate the p53 response to 5 Gy X-ray IR in WT
MEFs (Achison and Hupp, 2003; Parrinello et al., 2003; Wang
et al., 2006).
In addition to DNA damage, in response to non-DNA
damaging reagents, such as low levels of Act D, a similar pattern
of p53 stabilization was observed (Figure S5G). Together, these
data indicate that the Mdm2 E3 ligase function is critical for con-
trolling the magnitude of p53 activation in response to stress,
and restoring p53 to basal levels after stress.
Mdm2Y487A/Y487A Mice Demonstrate Increased
Radiosensitivity
The enhanced p53 stabilization and activity in Mdm2Y487A/Y487A
MEFs following stress, and the apparent inability of cells to
recover following activation of the p53-mediated stress
response, pointed to the importance of theMdm2E3 ligase func-
tion in regulating p53 following exposure to stressors. To test if
the aberrant activation of p53 observed in Mdm2Y487A/Y487A
MEFs would be replicated in vivo, WT and Mdm2Y847A/Y487A
mice were treated with a sublethal dose (5 Gy) of g IR. As ex-
pected, this dose of IR did not cause any immediate disease or
affect mortality in WT mice; however, in Mdm2Y847A/Y487A mice242 Cancer Cell 26, 235–247, August 11, 2014 ª2014 Elsevier Inc.5 Gy g IR resulted in significant weight
loss and 100% lethality by 22 days
posttreatment (Figures 6A and S6A). To
determine whether the observed pheno-
type is p53 dependent, Mdm2Y847A/Y487A
mice with concomitant deletion of
either one or both copies of p53 were
similarly treatedwith 5Gy g IR. In contrast
to Mdm2Y487A/Y487 mice with intact
p53, both Mdm2Y847A/Y487A;p53+/ and
Mdm2Y847A/Y487A;p53/ mice were re-
sistant to 5Gy g IR treatment and demon-
strated no significant changes in body
weight or viability (Figures 6B and S6B),
indicating that the lethality observedin the Mdm2Y847A/Y487A mice was p53 dependent. While
deletion of p53 can serve a protective function against the
short term consequences associated with exposure to IR,
including apoptosis and hematopoietic failure, we observed
increased survival in Mdm2Y487A/Y487A;p53+/ mice compared
to Mdm2Y487A/Y487A;p53/ mice; this observation supports the
idea that both too much p53, as in Mdm2Y487A/Y487A;p53+/+
mice, as well as too little or no p53, as in Mdm2Y487A/Y487A;
p53/ mice, can be deleterious (Donehower et al., 1992; Men-
drysa et al., 2003).
The gross examination revealed a significantly smaller spleen
and significantly lower levels of red blood cells and white blood
cells in Mdm2Y487A/Y487A mice compared to the WT (Figures
6C, S6C, and S6D). The time of death following treatment,
together with decreased splenic size and blood counts, is sug-
gestive of hematopoietic failure as the ultimate cause of death
in the irradiated mutant animals (Gudkov and Komarova, 2003;
Mendrysa et al., 2003; Wang et al., 2011).
The histological examination indicated that both WT and
Mdm2Y487A/Y487A mice have similarly low levels of p53 in the
spleen prior to IR and increased levels of p53 by 4 hr after treat-
ment with 5 Gy g IR (Figure 6E). In the presence of WT Mdm2,
p53 levels in the spleen returned to near untreated levels by
24 hr after 5 Gy g IR, while in theMdm2Y487A/Y487A spleen, dense
areas with high p53 remain (Figure 6E). Corresponding to
observations in the spleen, p53 levels were relatively low and
similar in the testes, intestine, and liver of untreated WT and
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however, p53 levels were higher in Mdm2Y487A/Y487A mice
compared to WT mice at 4 hr and 24 hr posttreatment in the in-
testine (Figure S6G) and at 24 hr in the testes (Figure S6F); the
liver is generally considered to be radioresistant and did not
demonstrate any changes in observed p53 (Figure S6H).
To assess the effect of the increase in p53 protein on p53 ac-
tivity, qRT-PCR of several p53 target genes, including p21,
Mdm2, Bax, and Tigar, in splenic and thymic tissue from WT
and Mdm2Y487A/Y487A mice was performed. Following 5 Gy g
IR, p53 activity is significantly higher in Mdm2Y487A/Y487A mice
compared to the WT, as indicated by higher mRNA expression
of p53 target genes, providing evidence that the higher p53 pro-
tein levels inMdm2Y487A/Y487Amice correlate with increased p53
activity (Figure 6G). The dynamics of the p53 stress response in
the spleen and thymus were further examined by western blot; in
response to 5 Gy g IR treatment, p21 was increased and main-
tained at a higher level in theMdm2Y487A/Y487Amutant compared
to theWT, further indicating that the accumulation of p53 protein
correlates with increased p53 activity (Figures 6D and S6I). To
infer the biological consequences of increased p53 levels and
activity in the mouse, TUNEL staining was utilized to assess
the level of apoptosis; in the spleen, corresponding to increased
p53 levels and activity, increased levels of apoptosis were
observed in Mdm2Y487A/Y487A mice following IR (Figure 6F).
DISCUSSION
Mdm2 has long been considered the gatekeeper of both p53 sta-
bility and activity, and as such, it is critically important to have a
thorough understanding of Mdm2-mediated p53 regulation
in vivo. It has long been accepted that Mdm2 E3 ligase activity
is an essential mechanism for Mdm2-mediated p53 regulation;
with this in mind, the most unanticipated finding of the current
study is that fully intact Mdm2 E3 ligase activity toward p53 is
dispensable in vivo, as demonstrated by the viability, normal
development, and lifespan of Mdm2Y487A/Y487A mice. In vivo,
the loss of Mdm2 E3 ligase activity resulted in increased stabili-
zation of p53, but loss of E3 activity alone, without disruption of
Mdm2:MdmX heterodimerization, was not sufficient to signifi-
cantly increase p53 activity. Following activation of the p53
pathway, Mdm2 E3 ligase function becomes essential in control-
ling p53 abundance and activity.
A number of recent knockin mouse models, including
MdmxDRING, MdmxC462A, and Mdm2C462A, have implicated
Mdm2:MdmX heterodimerization as an essential component of
p53 regulation, in large part due to the embryonic lethality
observed when this interaction is disrupted (Huang et al., 2011;
Itahana et al., 2007; Pant et al., 2011). In this regard, the
Mdm2Y487A model provided vital complementary data, further
pointing toward Mdm2:MdmX heterodimerization as the key to
understanding p53 regulation. Uniquely, the Mdm2Y487A model
allows for analysis of RING finger binding dynamics independent
of Mdm2 E3 ubiquitin ligase activity. In contrast with previous
in vitro data, the study of the Mdm2Y487A knockin mouse model
suggests that Mdm2 E3 ligase activity is significantly disrupted
even in the presence of Mdm2:MdmX heterodimerization (Oka-
moto et al., 2009; Poyurovsky et al., 2007; Uldrijan et al.,
2007). The apparent discrepancy between Mdm2Y487A in vitro,which demonstrated near normal levels of p53 stabilization in
the presence of MdmX, and in vivo, which demonstrated near,
if not complete disruption of p53 degradation, serves as an addi-
tional example as to the importance of examining proteins at
physiologically relevant levels.
While correlated with the regulation of p53 stability and activ-
ity, themechanism through which theMdm2:MdmX heterodimer
functions in these roles remains inadequately understood. In
concert with existing mouse models, we believe our data sup-
port the following model: Under unstressed conditions the
Mdm2:MdmX heterodimer is able to suppress p53 activity
through binding, conceivably by inhibiting p300-mediated p53
acetylation, without Mdm2mediated p53 degradation. Following
stress and the subsequent posttranslational modifications to
p53, Mdm2, and MdmX, p53 levels and activity are increased.
Once p53 has been stabilized and activated, the Mdm2:MdmX
heterodimer is no longer sufficient to control p53, and Mdm2
E3 ubiquitin ligase activity becomes critical for recovery from
the p53-mediated stress response (Figure 7).
Although MdmX is generally cytoplasmic, while Mdm2 and
p53 are primarily localized to the nucleus, theMdm2Y487Amouse
further implicates the interaction between Mdm2 and MdmX to
be critical in p53 regulation. An explanation for the apparent ne-
cessity for theMdm2:MdmX interaction is the role ofMdm2 in the
translocation of MdmX to the nucleus, as MdmX does not carry
its own nuclear localization signal or nuclear export signal (Li
et al., 2002; Marine and Jochemsen, 2005). Alternatively, the
fraction of Mdm2 and p53 localized to the cytoplasm may allow
for Mdm2:MdmX heterodimer formation and function; previous
data have implicated cytoplasmic MdmX in p53 regulation
(Jimenez et al., 1999; Moll et al., 1995; Ohtsubo et al., 2009).
Regardless, further investigation to characterize the mechanism
illuminating how Mdm2 and MdmX work together to inhibit p53,
despite differences in subcellular localization, remains an impor-
tant yet unresolved issue in the field.
In addition to implications on the role of Mdm2 E3 ligase activ-
ity in the regulation of p53 stability, theMdm2Y487Amousemodel
has also provided additional insight into Mdm2 degradation.
While the E3 ligase responsible for Mdm2 degradation in vivo
is yet to be identified, this model provides further evidence that
under physiological conditions autoubiquitination is not the pri-
mary mechanism for Mdm2 degradation. Additional research
into the regulation of Mdm2 stability, and identification of E3
ubiquitin ligases with specificity for Mdm2 are important ven-
tures to be explored.
Due to the high rate of p53 mutation, deletion, and misregula-
tion in many cancers, in theory, the p53 pathway is an attractive
drug target; however, effective therapeutics utilizing this
pathway are not yet found in the clinic (Danovi et al., 2004; Hai-
naut et al., 1997; Momand et al., 1998; Wade et al., 2013). As
brought to light by our study, the basic understanding of p53
regulation in vivo is continuing to evolve. The key findings from
this study have important clinical implications, as a number of
drugs targeting the Mdm2-p53 pathway, including Nutlin-3a,
were developed to target Mdm2:p53 interaction and/or Mdm2-
mediated ubiquitination of p53 (Vassilev et al., 2004; Wade
et al., 2013). Although many factors in the tumor microenviro-
ment are known to activate the p53 pathway, it remains to be
determined if, as observed in response to DNA damage,Cancer Cell 26, 235–247, August 11, 2014 ª2014 Elsevier Inc. 243
(legend on next page)
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Figure 7. Mdm2:MdmX Heterodimer Regulation of p53
Model depicting Mdm2:MdmX heterodimer regulation of p53 before and after
activation of the p53 stress response pathway.
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tivation in response to the tumor microenvironment itself (Bieg-
ing et al., 2014). Along with a number of recent knockin mouse
models, the Mdm2Y487A mouse points to the significance of
Mdm2:MdmX heterodimerization in both p53 stability and activ-
ity, and thus, disruption of this interaction may be a potent ther-
apeutic target. Focused study of the interaction between Mdm2
and p53 at physiological levels has provided additional insight
into both p53 and Mdm2 regulation, which will allow for more
effective application of therapeutics targeting this pathway, as
well as additional targets for the development of effective drugs.
EXPERIMENTAL PROCEDURES
Generation of Mdm2Y487A Knockin Mice
Murine 129/Sv genomic DNA containing the last six exons (7–12) ofMdm2was
a gift from Dr. Guillermina Lozano (University of Texas, M.D. Anderson Cancer
Center). The targeting vector was constructed in a phosphoglycerate kinase
neo vector previously described (Itahana et al., 2007). A Tyr-to-Ala substitution
(TAC to GCA) was introduced in codon 487 using site-directed mutagenesis.
The final construct was sequenced using overlapping primers. The University
of North Carolina (UNC) Animal Models Core Facility performed electropora-
tion of 129/Sv-derived AB2.2 ES cells. DNA isolated from G418-resistant ES
colonies was confirmed for the presence of the Y487A substitution by PCR
amplification of genomic DNA using primers flanking exon 12, followed by
sequencing. There were two positive clones that were injected into C57BL/6
blastocysts, and the blastocysts were transferred into pseudopregnant female
recipients. The resulting chimeric males were mated with C57BL/6 females;
PCR analysis and DNA sequencing confirmed germline transmission.
Following germline transmission of the Mdm2Y487A mutation, Mdm2Y487A/+
mice were mated with Ella-Cre transgenic mice (Jackson Laboratories, stockFigure 6. Mdm2Y487A/Y487A Mice Demonstrate Increased Radiosensitivi
(A) Kaplan-Meier survival curve forMdm2+/+ (WT) andMdm2Y487A/Y487A (487/487) f
the time of treatment.
(B) Kaplan-Meier survival curve for Mdm2Y487A/Y487A;p53+/+ (487/487;p53+/+), M
487;p53/) male mice treated with 5 Gy g-IR. Mice were between 6.5 and 7.5 w
(C) Representative gross histology ofMdm2+/+ andMdm2Y487A/Y487A spleens of 6
spleens were collected 14 days after treatment.
(D) The 14-week-oldMdm2+/+ andMdm2Y487A/Y487A female mice were treated wit
by western blotting for p21 levels. Actin was used as a loading control.
(E) Immunohistochemistry staining for p53 in splenic tissue fromMdm2+/+ (WT) an
(F) Splenic tissue from Mdm2+/+ (WT) and Mdm2Y487A/Y487A (487/487) mice left un
apoptosis.
(G) mRNA levels of the p53 target genes p21,Mdm2,Bax, and Tigar in the spleen a
untreated or treated with 5 Gy g IR as indicated were measured by qRT-PCR. M
analyzed in triplicate. Data are means ± SD normalized to GAPDH. n=3 for each ge
See also Figure S6.number 003724) to excise the neomycin selection marker. The resulting mice
were backcrossed to C57BL/6 for five generations. Mice were bred and main-
tained strictly under protocols 10-045 and 13-044, approved by the Institu-
tional Animal Care and Use Committee at the UNC at Chapel Hill Animal
Care Facility.
Mouse Breeding, Genotyping, and Experiments
PCR was utilized to identify theMdm2Y487A mutation using primers for the WT
(m305wF 50- TTATTGAAGGACTATTGGAAGTGTACCTCA-30; mY487A-W-R-4
50- GTGAGCAGGTCAGCTAGTTGAAGTA-30) and mutant (m305wF; mY487A-
M-R-1 50- TTGTGAGCAGGTCAGCTAGTTGAATGC-30) alleles. The Mdmx/
mice were a gift from Guillermina Lozano (University of Texas, M.D. Anderson
Cancer Center). The p53/ mice were purchased from The Jackson Labora-
tory (stock number 002101). PCR primers for WT (p53-X7, 50-GGATGGTGG
TATACTCAGAGCC-30; p53-X6, 50-ACAGCGTGGTGGTACCTTAT-30) and
mutant (p53-X7; NEO18.5, 50-TCCTCGTGCTTTACGGTATC-30 ) p53 alleles
were described by The Jackson Laboratory. p53ERTAM knockin mice were a
gift from Gerard Evan (University of Cambridge, UK) and genotyping of the
p53ERTAM alleles was performed as described previously (Christophorou
et al., 2005).
At 5.5 to 8.5 weeks of age, mice were treated with 5 Gy g IR (Mark I Model
68-1 Cesium–137 Irradiator) at a dose rate of 1.89 Gy/min. For survival studies
following IR, mice weremonitored andweighed every other day, andmoribund
mice were humanely euthanized. Mouse tissue was fixed in formalin for histo-
pathology and snap frozen in liquid nitrogen for protein extraction.
Cell Culture
Primary MEFs were cultured in a 37C incubator with 5% CO2, and 3% O2
in Dulbecco’s modified Eagle’s medium supplied with 10% fetal bovine
serum and penicillin (100 IU/ml)/streptomycin (100 mg/ml). For activation of
p53ERTAM, 100 nM 4-OHT dissolved in 100% ethanol was added to the culture
medium. MEFs were treated as indicated with 25 J/m2 UV, 5 nM Act D, 1 mM
Dox, or 5 Gy g IR.
Protein Analysis
Mouse monoclonal Mdm2 (2A10), MdmX (MdmX-82), p53 (NCL-505), phos-
pho-p53 (Ser15), acetyl-p53 (Lys320,), actin (MAB1501), and goat polyclonal
p21 (C-19) antibodies were purchased commercially. Rabbit polyclonal anti-
body to p21 was a gift from Yue Xiong (UNC-Chapel Hill). Mouse monoclonal
antibody to MdmX (7A8) was a gift from Jiandong Chen (University of South
Florida). MEFs were lysed in 0.1% NP-40 buffer for immunoprecipitation (IP)
and 0.5%NP-40 buffer for straight western blotting. Tissue was lysed in tissue
lysis buffer (0.2% Triton X-100, 0.3%NP-40). Procedures and conditions for IP
and immunoblotting were described previously (Itahana et al., 2003). Protein
crosslinking was performed prior to p53 IP as described previously (Clegg
et al., 2012; Itahana et al., 2007). The half-life of p53 and Mdm2 was measured
by treating cells with cycloheximide (100 mg/ml) for the indicated length of time,
followed by lysis in 2% SDS lysis buffer. The protein level was analyzed by
western blotting and the intensity of the bands in the linear range of exposure
was quantified by densitometry. Subcellular fractionation was performedty
emalemice treatedwith 5Gy g-IR. Micewere between 5.5 and 8.5weeks old at
dm2Y487A/Y487A;p53+/ (487/487;p53+/), and Mdm2Y487A/Y487A;p53/ (487/
eeks old at time of treatment.
.5-week-old male mice either untreated or treated with 5 Gy g-IR as indicated;
h 5 Gy g-IR. Splenic tissue harvested at the indicated time points was analyzed
dMdm2Y487A/Y487A (487/487) mice left untreated or after 5 Gy g IR as indicated.
treated or after 5 Gy g IR as indicated; TUNEL staining was used to assay for
nd thymus ofMdm2+/+ (WT) andMdm2Y487A/Y487A (487/487) female mice either
ice were between 11 and 18 weeks old at time of treatment. All samples were
notype in each treatment. *p < 0.05, ***p < 0.001 compared with control group.
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ufacturer’s instructions.
Quantitative Real-Time PCR
Total RNA was isolated using an RNeasy Kit and cDNA was synthesized using
SuperScript III. qRT-PCR was performed with SYBR green master mix using
the7900HT Fast Real-Time PCR System according to manufacturer instruc-
tions. Data were collected and exported with SDS 2.2.2 software. Relative
expression was calculated using GAPDH or Actin as an internal control as indi-
cated. Primers used were as follows: Mdm2, 50CCA ACCATCGACTTCCA
GCAGCATT30 and 50GAT TGGCTGTCTGCACACTGGG30; p21, 50CCTGGT
GATGTCCGACCTG30 and 50CCATGAGCG CATCGCAATC30; Apaf1, 50CGGT
GAAGGTGTGGAATGTCATTACCG30 and 50GGATTTCTCC ATTGTCATCTC
CAGTTGC30; Bax, 50GGACAGCAATATGGAGCTGCAGAGG30 and 50GGAGG
AAGTCCAGTGTCCAGCC30; TIGAR, 50CGATCTCACGAGGACTAAGCAGA
CC30 and 50GCCA AAGAGCTTTCCAAACCGCTGC30; GAPDH, 50AGGTC
GGTGTGAACGGATTTG30 and 50TGTA GACCATGTAGTTGAGGTCA30; Actin,
50CCACAGCTGAGAGGGAAATCGTGC 30 and 50CCAG AGCAGTAATCTCC
TTCTGCATCC30; and p53, 50ATGGAGGAGCCGCAGTCAGATC30 and 50CCA
TTGTTCAATATCGTCCGGG30.
Immunohistochemistry and TUNEL Staining
Tissue from Mdm2+/+ and Mdm2Y487A/Y487A mice was harvested and fixed in
10% formalin for 24 hr. There were five micrometer sections that were stained
by immunohistochemistry for p53 (NCL-p53-CM5p) and 3,3’-Diaminobenzi-
dine staining. TUNEL staining for apoptosis was performed using the Apoptag
Peroxidase In Situ Apoptosis Detection Kit according to manufacturer’s in-
structions. Stained tissue was analyzed using an Olympus IX-81 microscope
fitted with a SPOT camera and software.
Statistical Analysis
Statistical analysis was carried out using GraphPad Prism 4 Software. For life-
span analysis and IR experiments, a Kaplan-Meier survival curve was carried
out. A two-tailed unpaired t test analysis was utilized to compare mRNA levels
in qRT-PCR experiments.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and can be found with article
online at http://dx.doi.org/10.1016/j.ccr.2014.06.006.
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